406 results on '"Kim, S.T."'
Search Results
2. Performance Evaluation for K-WAMS (Korean wide area Monitoring System) under Field Operating Condition of Korea Power Grid
3. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer
4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer
5. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
6. A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
7. Donor Hearts with Low EF for Heart Transplantation
8. Evaluating Mid-Term Outcomes of COVID-19 Donor Heart Transplantation in the United States
9. Characterizing the Impact of Donor Sequence Number on Outcomes Following Heart Transplantation
10. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆
11. Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment
12. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
13. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
14. Adapting the MgO-CO2 working pair for thermochemical energy storage by doping with salts
15. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
16. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
17. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
18. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
19. (273) Postoperative Renal Failure in Patients Undergoing Isolated Heart Transplantation: What are the Outcomes?
20. Lung Transplantation from HCV NAT+ Donors: Reassuring Mid-Term Outcomes
21. (256) Ex-Vivo Lung Perfusion May Have a Detrimental Impact on Lung Transplants from Donation after Circulatory Death Donors
22. (405) Predictors and Outcomes of Post-Operative Extracorporeal Membrane Oxygenation at 72 Hours Following Lung Transplantation
23. (59) Mid-Term Outcomes of Heart Transplants from HCV NAT+ Donors
24. (70) Normothermic Regional Perfusion in Donation after Circulatory Death Heart Donors May Not Have a Detrimental Effect on Lung Transplant Outcomes
25. Verification of radiation heat transfer analysis in KSTAR PFC and vacuum vessel during baking
26. Detection of low-frequency oscillation using synchrophasor in wide-area rolling blackouts
27. Chen, Jun. Detecting regime change in computational finance: data science, machine learning and algorithmic trading
28. Core clinical symptoms and suicidal ideation in patients with obsessive compulsive disorder – a network analysis
29. (906) - Does Donor-Recipient Age Mismatch Impact the Recipient's Survival in Lung Transplantation?
30. (907) - Outcome of COVID-19 Positive Donor Lung Transplantation
31. (905) - Lung Transplantation for COVID-19 Lung Failure: Does Bridging with ECMO Impact Outcomes?
32. (1231) - Donor Hearts with Low EF for Heart Transplantation
33. (1230) - Older Donor Hearts for Heart Transplantation
34. (237) - Donation After Circulatory Death for Heart Transplantation
35. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
36. Improvement of initial vacuum condition along 2008–2010 KSTAR campaign by vessel baking
37. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy
38. 1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A
39. 529P A phase Ib trial of belvarafenib in combination with cobimetinib in patients (pts) with RAS- or RAF- mutated (m) solid tumors: Updated safety data and indication-specific efficacy results
40. 1048P Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
41. Impact of Frailty on Acute Outcomes of Endovascular Thoracic and Abdominal Aneurysm Repair
42. Wall conditioning of the KSTAR vacuum vessel
43. Effect of botulinum toxin type A injection into human masseter muscle on stimulated parotid saliva flow rate
44. P-214 Salvage Chemoradiotherapy for Locally Recurrent Bile Duct Cancer
45. P-106 Anxiety and depression as predictive factors for quality of life in patients with newly diagnosed advanced gastrointestinal cancer
46. Nonylphenol
47. PREDICTORS FOR SUCCESS OF INTRAUTERINE INSEMINATION: A RETROSPECTIVE ANALYSIS
48. 661MO Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation
49. 618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
50. (906) - Does Donor-Recipient Age Mismatch Impact the Recipient's Survival in Lung Transplantation?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.